- The European Commission has granted marketing authorisation to US-based AbbVie for Maviret (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naive, compensated cirrhotic
, chronic hepatitis C patients with genotype 1, 2, 4, 5, or 6 infection, US-based biotechnology company Enanta Pharmaceuticals, Inc.
Release date- 02082019 - NORTH CHICAGO - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission has granted marketing authorization for MAVIRET to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naive, compensated cirrhotic
, chronic hepatitis C (HCV) patients with genotype (GT)1, 2, 4, 5, and 6 infection.
The multicenter, open-label PANASH study will evaluate the safety and preliminary efficacy of Promethera's allogenic cell-based therapy for severe liver diseases, in patients with cirrhotic
and pre-cirrhotic NASH.
2018;69:958-60).The term cirrhotic
cardiomyopathy has also been used for the changes of systolic dysfunction with impaired cardiac contractile response to stress and altered diastolic relaxation that develops in patients with cirrhosis (J Hepatol.
Several retrospective studies have shownthat SAAG and serum albumin as probable noninvasive biochemical markers of esophageal varices in cirrhotic
patients and SAAG has been concluded an indirect biochemical marker in detecting the occurrence and grades of esophageal varices as a n endoscopic parameter of portal hypertension.
Karachi -- Pakistan may be turned into a 'cirrhotic
state' and Hepatitis C may be second polio for the country if we don't start mass awareness and screening of our population of the viral hepatitis, which is now a completely treatable and curable disease.
In HCV patients who do not have cirrhosis but have achieved Sustained Virological Response (SVR), the risk of developing HCC is lower compared to cirrhotic
HCV patients, even after the attainment of SVR, the risk of HCC still persists.
This cross-sectional study was conducted on 359 HCV positive cirrhotic
patients attending the Tanta University School of Medicine Hospital.
Besides, differentiating multicentric occurrence (MO) from intrahepatic metastasis (IM), multiomics profiling could provide essential information to evaluate the aggressiveness of existing lesions and apply personalized therapies as well as postsurgical treatment. D-HCC occurs as an occult disease, providing few specific clinical manifestations, it resembles cirrhotic
nodules on imaging, resulting in frequent misdiagnosis.
Besides the hepatorenal syndrome this has led to the recognition of new clinical entities, such as cirrhotic
cardiomyopathy and the hepatopulmonary syndrome.
The complications and mortality after the first UGB on the cirrhotic
patient can be determined by multiple factors: the source of hemorrhage(the rupture of esophageal varices, gastric or duodenal ulcer, portal-hypertensive gastropathy, the rupture of the gastric varices, hemorrhagic gastritis, Mallory-Weiss syndrome, etc.), the gravity of the hemorrhage (hemodynamic impact, etc.), aggravation of the hepatic failure (appreciated by Child-Pugh criteria), other pathologies association (infections, diabetes, chronic respiratory diseases).